Thomas D. Anderson

Mr. Anderson has served as a director of Zevra Therapeutics since August 2023. As a 35-year veteran of the biopharma industry, he has led high-growth organizations throughout his career. He currently serves as CEO and Director at SwanBio Therapeutics, a clinical-stage gene therapy company that aims to bring life-changing treatments to people with devastating and inherited neurological conditions. Prior to SwanBio Therapeutics, Mr. Anderson served as the Chief Commercial Officer of Sage Therapeutics, a key member of the company’s leadership team. From 2004 and 2014, Mr. Anderson was a senior executive with Shire Pharmaceuticals Group in a number of operational and strategic roles in both rare diseases and specialty pharmaceuticals. Earlier in his career, Mr. Anderson was with J&J (Janssen and McNeil Pharmaceutical) in a number of leadership, sales, marketing, and business information roles which experienced transformational growth.

Mr. Anderson earned his MBA from the University of Notre Dame’s Mendoza College of Business Administration. He received his BS in civil engineering from the P.C. Rossin College of Engineering at Lehigh University.